GeoVax Hands Lender Three Board Seats for $1M Revolver, Commits to $10M Equity Raise
GOVX is trading near its 52-week low of $0.19 (5.5% above the low) on light trading volume (0.3× avg).
Summary
GeoVax signed a $1M revolver with Bowery Consulting that gives the lender three of five board seats and obligates the company to pursue at least $5M — $10M in total by December 31, 2026 — in registered equity offerings. No money has been drawn and every advance is at the lender's discretion.
Key Events · Financing and Capital Events · GOVX
-
Lender Takes Board Majority
Five directors resigned October 23, 2026 and three Bowery-designated nominees — Steven Brown, Tyler O'Brien and Manpreet Uppal — were appointed, giving the lender three of five seats and a majority of each committee.
-
$1M Revolver, Zero Drawn
The unsecured facility carries 12% interest (16% default rate), matures one year after closing, and every drawdown is at the lender's sole and absolute discretion; no principal is outstanding.
-
Forced $5M-$10M Equity Raise
GeoVax must use reasonable best efforts to complete a registered offering of at least $5,000,000, and at least $10,000,000 in aggregate with additional offerings by December 31, 2026 — or the new directors automatically resign.
-
Lender Veto Rights
While loans are outstanding the company cannot change executive compensation, hire officers or consultants, pay dividends, buy back stock above thresholds, or take on new debt without a 10-day right of first refusal going to Bowery.
Analysis · GOVX · Life Sciences
GeoVax's new $1M revolver is not really about the $1M. Bowery Consulting gets three of five board seats, a majority of every committee, and veto rights over pay, hiring, dividends and buybacks — and the company must use reasonable best efforts to raise at least $5M in a registered equity offering, with $10M in total required by December 31, 2026 or the new directors automatically resign. Against $3.1M of cash that only funded operations into September 2026, this is a rescue package on the lender's terms: the dilution from the forced raise is the real cost, and the board purge removes independent oversight at the moment the company is asking shareholders to approve a reverse split and 11.4M new warrants at the October 27 meeting. Drawdowns are entirely at the lender's discretion, so the $1M is not even assured.
How filings like this one have moved
In the 30 days to Oct 27, 2026, 45.6% of the 241 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.73%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GOVX was trading at $0.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2M. The 52-week trading range was $0.19 to $15.17. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.